stockrow
Friday 6 November 2026
Export MAZE’s income statement to Excel — free account
Maze Therapeutics, Inc.
MAZE Healthcare Biotechnology
Maze Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $167.5 million.
- EPS
- +1.30%
- Free cash flow
- +50.2%
Quarter to June 2026, against a year earlier
34.24
1.71
+5.26%
Follow MAZE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 168 | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (115) | (100) | 53 | (131) | (134) | +4.5% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 31.88 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (115) | (100) | 52 | (131) | (134) | +4.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 69.91 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (57.21) | (43.89) | 1.42 | (3.05) | (2.52) | (62.4%) | ||||||
| Cash flow | — | — | — | — | — | — | (49.38) | (37.95) | 31.70 | (2.60) | (1.81) | (62.5%) | ||||||
| Capex | — | — | — | — | — | — | (0.98) | (0.19) | (0.48) | (0.02) | (0.01) | (73.4%) | ||||||
| Free cash flow | — | — | — | — | — | — | (50.36) | (38.14) | 31.22 | (2.62) | (1.81) | (62.7%) | ||||||
| Book value | — | — | — | — | — | — | (140.60) | (163.40) | (129.88) | 8.26 | 7.68 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 2 | 2 | 2 | 43 | 50 | +177.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | — | 4.46 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (1.84) | — | (15.42) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (99) | (87) | 76 | (112) | (107) | +4.1% | |||||
| Capex | — | — | — | — | — | — | (2) | 0 | (1) | (1) | 0 | (26.1%) | ||||||
| Free cash flow | — | — | — | — | — | — | (101) | (87) | 75 | (113) | (107) | +3.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 85 | 18 | 181 | 327 | 397 | +56.5% | |||||
| Net debt | — | — | — | — | — | — | (100) | (9) | (197) | (342) | (372) | +50.7% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (282) | (374) | (311) | 355 | 453 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (90.68) | 2.18 | (41.12) | (31.99) | (41.1) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (684.43) | (112.36) | (684.4) pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 30.60 | (0.99) | (598.95) | (37.35) | (598.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 121 | 125 | 141 | — | +7.9% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 1.34 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026
Maze Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRAX First Tracks Biotherapeutics, Inc. | $1.9B | — (loss-making) | — | — | n/m | +55.91% (above 0%: growing) | — | 0.00% | Compare |
| REPL Replimune Group, Inc. | $1.9B | — (loss-making) | — | — | n/m | +42.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HRMY Harmony Biosciences Holdings, Inc. | $1.9B | 10.7× | 9.9× | +12.30% (above 0%: growing) | −6.24% (below 0%: shrinking) | −29.42% (below 0%: shrinking) | 70.00% | 20.15% | Compare |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | — (loss-making) | 6.3× | −4.51% (below 0%: shrinking) | n/m | +231.84% (above 0%: growing) | 0.00% | (2.37%) | Compare |
| VIR Vir Biotechnology, Inc. | $1.9B | — (loss-making) | — (loss-making) | −178.33% (below 0%: shrinking) | n/m | +200.47% (above 0%: growing) | 100.00% | 55,669.15% | Compare |
| MESO Mesoblast Limited | $1.8B | — (loss-making) | — | −13.41% (below 0%: shrinking) | n/m | −89.23% (below 0%: shrinking) | (353.35%) | (909.40%) | Compare |
| TRVI Trevi Therapeutics, Inc. | $1.8B | — (loss-making) | — | — | n/m | −73.77% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MAZE Maze Therapeutics, Inc. | $1.8B | — (loss-making) | — | — | n/m | +50.21% (above 0%: growing) | 100.00% | 0.00% | |
| MRVI Maravai LifeSciences Holdings, Inc. | $1.8B | — (loss-making) | — (loss-making) | +10.14% (above 0%: growing) | n/m | +123.88% (above 0%: growing) | 35.31% | (44.97%) | Compare |
| Median of peers | $1.9B | — | — | −4.51% | — | +49.07% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 28 April 2026
Ownership
Directors and executive officers, together
5.30%
Entities affiliated with Third Rock Ventures
10.90%
Entities affiliated with Frazier Life Sciences
9.90%
Entities affiliated with Deep Track Capital, LP
9.90%
Entities affiliated with ARCH Venture Partners and related entities
8.30%
Janus Henderson Group PLC
6.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement